Dapirolizumab Pegol

Systemic lupus erythematosus (SLE)

Stage (next event)

Expected Date

Phase 3

Q4 2020

Catalyst Info & Data Links

Potential Catalyst Date

  • TBD

Clinical Trial

  • NCT04294667: A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

  • NCT02804763: A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus

Related Links

Prior Work/Results

HC updated 5/27/20

Prior Data (click to view full image)


Trial Design / Revenue (click to view full image)


Recent Posts

See what the community is saying - click to see full post

Amp Up July 2018

ASCO 2018 Amp Noteworthy Abstracts

March 2018 Amp Up

Summary of AMP Trades in December

AMP Trades Last Week

AMP trims position in NKTR

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon